Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

Despite advances, #familial #hypercholesterolaemia is still inadequately diagnosed and undertreated, with many affected people remaining at high risk of early #cardiovascular disease www.thelancet.com/journals/lan...
#HeFH #HoFH #ASCVD

#MedSky #EndoSKY #CardioSky

#HoFH #Zebra

Now on demand: This expert-led #CME program explores modern HoFH management, including emerging LDL-C therapies and practical strategies to optimize care.

Watch now: bit.ly/4cu703X

#HoFH #CardiologyCME #LDLCManagement #MedicalEducation

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

With major advances in knowledge about the disease, #familial #hypercholesterolaemia has become an exemplar for the practice of precision and personalised medicine thelancet.com/journals/lan...
#HoFH #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Evinacumab in HoFH: Sex-Specific Insights 🧬
New ELIPSE OLE data examine baseline traits and response to evinacumab in females vs males with homozygous familial hypercholesterolemia — advancing understanding of individualized therapy in HoFH.
👉 https://ow.ly/aMb250Yifa2
#HoFH

Join our expert-led #CME program on HoFH management. Explore new LDL-C therapies and case-based care strategies.

Register now: bit.ly/4cu703X

#HoFH #CardiologyCME #LDLCManagement #MedicalEducation

Groundbreaking Insights on Sex Differences in Rare Cholesterol Disorder Published in AJPC The AJPC's latest issue features a pivotal study revealing significant sex-based differences in cholesterol treatment response among HoFH patients, marking a crucial step forward in cardiovascular research.

Groundbreaking Insights on Sex Differences in Rare Cholesterol Disorder Published in AJPC #United_States #Boulder #Regeneron #AJPC #HoFH

The application of implementation science to expanding knowledge of #familial #hypercholesterolaemia has enabled the development and design of potentially more effective models of care thelancet.com/journals/lan...
#HoFH #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? www.thelancet.com/journals/lan...
#zodasiran #HoFH #LDL #cholesterol

#MedSky #EndoSky #CardioSky

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial Quarterly dosed zodasiran shows evidence of reductions in LDL cholesterol with a favourable safety profile, in patients with HoFH receiving background lipid-lowering therapy. Further investigation in ...

Quarterly dosed #zodasiran shows evidence of reductions in #LDL #cholesterol with a favourable safety profile, in patients with #HoFH receiving background lipid-lowering therapy www.thelancet.com/journals/lan...
#homozygous #familial #hypercholesterolaemia

#MedSky #EndoSky #CardioSky

Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? thelancet.com/journals/lan...
#HoFH

#MedSky #EndoSky #CardioSky

New—Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with #homozygous #familial #hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial thelancet.com/journals/lan...
#HoFH

#MedSky #EndoSky #CardioSky

Early Identification Starts Here: Free #CardioSmart FH Handouts 📃 for use at the point of care to explain the types of FH, including #HoFH, & guide conversations with your patients about diagnosis & treatment.

Order now, while supplies last. https://bit.ly/4pmvU9B

#CardioSky #Cholesterol

Despite advances, #familial #hypercholesterolaemia remains an underdiagnosed and untreated condition, with an urgent need for the design and implementation of effective models of care www.thelancet.com/journals/lan...
#ASCVD #HeFH #HoFH

#MedSky #EndoSky #CardioSky

Homozygous Familial Hypercholesterolemia (HoFH) is a rare disorder causing extremely high LDL cholesterol from birth, leading to early cardiovascular issues if untreated.

May 4 is #HoFH Awareness Day - familyheart.org

You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness

Protein-binding therapy: a new approach to lower cholesterol Homozygous familial hypercholesterolaemia affects approximately 30 000 individuals worldwide.1,2 Patients have untreated high plasma LDL cholesterol over 10 mmol/L; physical signs include arcus cornea...

Robert A Hegele comments on:
Protein-binding therapy: a new approach to lower #cholesterol www.thelancet.com/journals/lan...
#HoFH

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial The LDL cholesterol response was highly variable, but generally similar in patients treated with both lerodalcibep and evolocumab. Importantly, the study showed the inability to predict response based...

Lerodalcibep and evolocumab for the treatment of #homozygous #familial #hypercholesterolaemia with #PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial www.thelancet.com/journals/lan...
#HoFH #LDL #cholesterol

#PrimaryCare and #cardiology providers: What are your next steps for patients newly diagnosed with #HoFH? Beyond treatment, who else would you screen? Dr. Patrick M. Moriarty shares expert insights: bit.ly/3zNNrT9